Аналитика NYSE на 30 сентября
Спайдер снижается перед открытием торгов на NYSE.
- Европейские индексы на отрицательной территории.
SPY (внутридневной график) снижение на премаркете. Поддержка 167.50, сопротивление 168.00
Премаркет NYSE/NASDAQ:
Gapping up:
- In reaction to strong earnings/guidance: CRRS +7.8%.
- M&A news: ACTV +27.4% (Active Network to be acquired by Vista Equity Partners; stockholders to receive $14.50 per share), CHRM (Charm Communications announces receipt of 'going private' proposal priced at $4.70 per ADS).
- Other news: DCTH +30% (received Orphan Drug Designation for Treatment of patients with hepatocellular carcinoma ), ORB +8% (Orbital Sciences' unmanned cargo ship has reached the Intl space station, according to reports), QCOR +4.6% (still checking), NSPH +4.3% ( Study Demonstrates Significant Clinical and Economic Impact of Nanosphere's Verigene Blood Culture Test; Average per Patient Hospital Cost Savings of $60,000 and 22 Day Reduction in Length of Stay Observed), ZAZA +4% ( Announces Second Transaction with JV Partner to Acquire Additional Production and Further Develop Its Eaglebine/Eagle Ford East Assets), RMTI +3.1% (continued strength), CYTR +1.8% (reports new Aldoxorubicin data that demonstrates significant advantages over doxorubicin; provides additional updates on other Phase 2 studies ), HALO +1.8% (presents PEGPH20 Phase 1b clinical trial data that suggest a potential clinical benefit of using PEGPH20 with gemcitabine in patients with high levels of tumor associated hyaluronan), HNR +1.4% (announces exclusive negotiations to sell interest in Gabon for $137 mln in cash), AZN +0.6% (NKTR reported that partner AZN announced European Medicines Agency acceptance of Marketing Authorisation Application for Naloxegol), PMT +0.6% ( Hayman Capital Management discloses 5.1% passive stake in 13G filing out Friday after the close).
(
Читать дальше )